Navigation and service

You are here:Rote-Hand-Briefe and Information Letters

Dear Doctor Letter (Rote-Hand-Brief) on darunavir/cobicistat: Increased risk of therapeutic failure and mother-to-child transmission of HIV

Date 2018.06.25
Active substance darunavir, cobicistat

The company Janssen-Cilag GmbH is circulating information on the fact that treatment with darunavir/cobicistat should not be initiated during pregnancy.